Critical appraisal:De Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al 2011
From Cancer Guidelines Wiki
Critical Appraisal
Article being appraised
de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011 Mar 10;29(8):1067-74 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21282537.
Applicable clinical question
Key Facts
Study Design
randomised controlled trial
Number of Patients:
534
Includes an economic evaluation
no
Evidence ratings
Level of evidence
II
Risk of bias
| Low risk of bias | Comments: Patients (N = 534) were randomly assigned to receive vandetanib 100 mg/d plus pemetrexed 500 mg/m(2) every 21 days (n = 256) or placebo plus pemetrexed (n = 278). |
Size of effect
| 1 | Reason for decision: This study did not meet the primary end point of statistically significant PFS prolongation with vandetanib plus pemetrexed versus placebo plus pemetrexed (HR, 0.86; 97.54% CI, 0.65 to 1.13; P = .219). |
Relevance of evidence
| 2 | Additional comments: PFS was the primary end point |
Result of appraisal
Included
Completed by
This appraisal has been completed.
- Article
- de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011 Mar 10;29(8):1067-74 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21282537.
- Assigned to
- User:Nick.pavlakis
- Topic area
- Guidelines:Lung cancer/Treatment/Non-small-cell stage IV inoperable
- Clinical question
Section below only relevant for Cancer Council Project Officer